MCT11 blockade led to minimal changes in CD8+ T cell infiltration (Extended Data Fig. 9a,b), coinhibitory marker expression and cytokine production in B16 tumor infiltrates (Fig. 5b,c), which was not surprising given the relatively minor effect of αMCT11 therapy on B16 tumor burden. The gene discussed is SLC16A11; the disease is neoplasm.